KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accounts Payables: 2017-2025

Historic Accounts Payables for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $267.0 million.

  • Moderna's Accounts Payables fell 28.42% to $267.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.0 million, marking a year-over-year decrease of 28.42%. This contributed to the annual value of $405.0 million for FY2024, which is 22.12% down from last year.
  • Latest data reveals that Moderna reported Accounts Payables of $267.0 million as of Q3 2025, which was up 52.57% from $175.0 million recorded in Q2 2025.
  • Moderna's 5-year Accounts Payables high stood at $520.0 million for Q4 2023, and its period low was $8.0 million during Q1 2021.
  • In the last 3 years, Moderna's Accounts Payables had a median value of $310.0 million in 2023 and averaged $329.2 million.
  • As far as peak fluctuations go, Moderna's Accounts Payables spiked by 2,387.50% in 2022, and later crashed by 52.96% in 2024.
  • Quarterly analysis of 5 years shows Moderna's Accounts Payables stood at $302.0 million in 2021, then surged by 61.26% to $487.0 million in 2022, then increased by 6.78% to $520.0 million in 2023, then dropped by 22.12% to $405.0 million in 2024, then fell by 28.42% to $267.0 million in 2025.
  • Its Accounts Payables stands at $267.0 million for Q3 2025, versus $175.0 million for Q2 2025 and $226.0 million for Q1 2025.